Size, Share & Industry Analysis, By Type (Software, Hardware), By Application (Public Hospital, Private Hospital, Diagnostic Imaging Centers, Teleradiology Providers), By End User (Radiologists, Healthcare Institutions, Imaging Equipment OEMs), By Imaging Modality (X-ray / CXR, CT, MRI, Ultrasound, Mammography / DBT, Nuclear Medicine / PET), and Global Forecast, 2026-2034
Explore the report section by section.
The global AI Medical Imaging Market was valued at USD 1.64 billion in 2025 and is estimated at USD 2.18 billion in 2026. Imaging-related AI revenue is projected to reach USD 20.53 billion in 2034, a 32.4% CAGR during 2026–2034.
In-scope revenue is attributable to AI-enabled medical image interpretation, triage, reconstruction, acquisition assistance and related software licensing or subscriptions. For imaging systems with embedded AI, only the incremental AI software or functionality value is included, not the entire CT, MRI or ultrasound scanner selling price. General-purpose clinical AI, electronic records and non-imaging ECG analytics are excluded. The FDA said it had authorized more than 1,600 AI-enabled medical devices by September 2026, while its public list identifies radiology as a major application category.
The UK government announced in 2026 a GBP 20 million program to expand AI-supported chest X-ray analysis to NHS trusts in England by 2029. Hospitals buy imaging algorithms when clinical validation, regulatory authorization and integration with PACS or radiology workflows can reduce reading delays or standardize measurements. Vendors earn software license, platform subscription, usage or AI-attributable equipment value, with adoption governed by clinical evidence and local reimbursement.
Philips introduced its AI-enabled SmartSpeed Precise MRI technology in 2025, and GE HealthCare launched AI-supported breast ultrasound and image-reconstruction products during the same year. FDA authorization applies to a specific device and intended use, not to every AI claim a vendor makes. Imaging datasets can differ by scanner, disease prevalence and patient group, requiring local validation, monitoring and human clinical oversight.
Source: FDA; FDA; FDA; UK Government.
AI Medical Imaging Market revenue includes separately sold clinical AI imaging software, attributable intelligent scanner modules and implementation services directly connected to diagnostic imaging. Entire conventional CT, MRI and X-ray scanner prices are excluded when no separable AI value can be identified.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Hardware; Software |
| By Application | Public Hospital; Private Hospital; Diagnostic Imaging Centers; Teleradiology Providers |
| By End User | Radiologists; Healthcare Institutions; Imaging Equipment OEMs |
| By Imaging Modality | X-ray / CXR; CT; MRI; Ultrasound; Mammography / DBT; Nuclear Medicine / PET |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; United Kingdom; India; Brazil; South Africa |
| Key Market Players | GE HealthCare; Siemens Healthineers; Philips; Aidoc; Viz.ai; Lunit; Qure.ai; Annalise.ai; Canon Medical Systems; Fujifilm; Brainomix; Hologic |
Revenue includes AI-enabled diagnostic image interpretation, quantitative imaging, automated reconstruction, prioritization, workflow software and incremental AI modules bundled with imaging systems. General scanner hardware revenue, ordinary radiology interpretation fees, and non-imaging clinical AI products are excluded to prevent double counting.
Application assigns the purchasing institution; End User identifies the principal user or integration customer. Public Hospital and Private Hospital are treated separately, and Imaging Equipment OEMs count only the identifiable AI functionality supplied or licensed rather than their entire imaging-equipment turnover.
The UK government said in 2026 that AI chest X-ray systems were already deployed in about half of NHS trusts in England and could help reduce complex reporting delays. Algorithms can flag suspected disease and improve image reconstruction, allowing radiologists to prioritize studies without replacing clinical interpretation. Hospitals still need integration with image archives, worklists and reporting systems to realize throughput gains. Workflow purchasing decisions depend on measured turnaround time and false-alert burden, not algorithm accuracy in isolation. Software vendors earn recurring revenue when hospitals renew deployments across multiple imaging sites.
The FDA maintains a public list of authorized AI-enabled devices and emphasizes that each entry has undergone applicable premarket review. Its January 2025 draft guidance recommends life-cycle risk management for AI-enabled software functions. Suppliers must document intended use, data quality, software changes and post-market performance before expanding deployment. EU medical AI products face additional risk-management and human-oversight requirements under the AI Act and medical-device regulations. Compliance costs favor companies with clinical evidence and dedicated regulatory teams, while narrowing claims that can be marketed.
GE HealthCare launched AI-supported Invenia ABUS Premium in March 2025 and introduced CleaRecon DL for cone-beam CT in May. Philips described faster MRI scanning and improved image sharpness from SmartSpeed Precise in 2025. These developments shift some spending from standalone algorithms toward embedded reconstruction and acquisition assistance. Hospitals may prefer integrated tools because existing service contracts simplify deployment, but bundled scanner prices cannot be treated entirely as AI revenue. Manufacturers compete on workflow efficiency, image quality and installed-base compatibility.
WHO guidance on large multimodal AI models warns that training-data gaps and automation bias can undermine clinical decisions. Medical imaging algorithms must be evaluated across scanners, hospitals, patient characteristics and disease prevalence to reduce unexpected performance drift. The FDA draft life-cycle guidance and Health Canada consultations emphasize documentation and managed changes. Hospitals therefore require audit trails, human review and escalation protocols before using automated triage at scale. These safeguards increase implementation expense but support long-term contracts when outcomes are documented.
AI imaging vendors offer subscriptions, per-scan fees and enterprise licenses, while health systems compare those costs with measurable labor savings and faster patient pathways. England announced GBP 20 million for chest X-ray AI deployment, demonstrating that public purchasing can accelerate diffusion beyond early pilot hospitals. In the United States, product-specific coverage and provider budgeting determine whether algorithms are paid separately or absorbed into imaging-service costs. Procurement committees also consider cybersecurity, PACS compatibility and performance monitoring. Uncertain reimbursement for AI imaging functions can lengthen hospital enterprise sales cycles.
Sources: FDA; UK Government; European Commission; WHO; Health Canada.
Philips announced Image Management 15 in November 2025 with a web diagnostic viewer and interfaces to connected AI tools. Consolidated PACS and visualization environments can deliver multiple algorithms without requiring radiologists to switch workstations. Hospitals increasingly assess integration costs and reporting efficiency across the full imaging pathway rather than buying isolated applications. Independent developers can distribute through established platforms, while platform owners gain negotiating leverage through installed bases. Interoperability and transparent clinical performance remain essential for vendor-neutral deployment.
Philips described SmartSpeed Precise MRI scans completed up to three times faster in its 2025 product announcement, based on company-reported performance measures. GE HealthCare added deep-learning reconstruction to interventional cone-beam CT through CleaRecon DL. Reconstruction applications differ commercially from disease-detection software because they can influence scanner utilization, image quality and protocol selection. Facilities purchasing equipment upgrades may value AI functionality as part of capital planning. Suppliers must separate AI-attributable value from the underlying scanner revenue when assessing market demand.
Viz.ai received FDA 510(k) clearance for its Subdural Plus measurement software in June 2025, adding automated CT quantification of subdural collections. Time-critical neuroimaging applications can shorten escalation pathways when notifications reach the responsible specialist promptly. Clinical adoption requires careful threshold selection and oversight because unnecessary alerts may burden teams. Developers are extending workflows beyond single abnormality detection into measurements and longitudinal comparison. The commercial opportunity lies in repeatable integration with stroke and neurosurgical care networks.
The UK government committed GBP 20 million in 2026 to expand AI-supported chest X-ray analysis across NHS trusts in England by 2029. Such procurement programs can create common evaluation requirements, including turnaround-time measurement, data protection and operational support. Vendors with robust clinical validation may gain access to multi-hospital contracts, while smaller firms must demonstrate integration capacity. Implementation still varies by radiology workforce, scanner mix and local reporting arrangements. Public investment can convert pilot studies into recurring subscription revenue.
The European Commission published a June 2025 FAQ addressing the interaction between the EU AI Act and medical-device regulations. Health Canada has consulted on predetermined change-control plans for machine-learning-enabled medical devices, and the FDA has proposed life-cycle documentation expectations. Vendors operating internationally must align intended use, version control, human oversight and monitoring across regulatory systems. Reusable evidence packages can reduce repeated development effort, but local data and language validation remain necessary. Medical-device regulatory compliance can determine eligibility for public hospital purchasing tenders.
The AI Medical Imaging Market includes Software and Hardware that incorporates identifiable clinical AI value. FDA authorizations cover stand-alone algorithms and intelligent imaging systems, while contracts range from per-study analysis to installed reconstruction modules.
Software represented an estimated ~79% of 2025 revenue. Aidoc and Viz.ai sell image-based triage and quantification applications, while radiology platforms integrate worklist alerts with PACS and reporting. Regulatory documentation, cybersecurity review and local performance evaluation shape software deployment; recurring licensing helps hospitals expand use without replacing their imaging fleets.
Hardware captures only incremental AI functionality embedded in scanners and dedicated processing appliances, not conventional scanner sales. Philips SmartSpeed Precise and GE HealthCare True Definition DL demonstrate image reconstruction features sold with compatible MRI or CT systems. Hospitals weigh throughput gains against capital budgets, system interoperability and maintenance obligations before purchasing AI-enabled equipment.
Software retains the largest revenue share through the forecast, while integrated hardware benefits when replacement cycles allow hospitals to procure intelligent acquisition and reconstruction at the scanner level. GE HealthCare and Philips have both obtained regulatory clearance for defined reconstruction functions. Software vendors must distinguish diagnostic triage from image enhancement because each intended use has separate evidence and clinical integration requirements. Vendor support for installed scanners can also affect how rapidly hospitals deploy upgrades after purchase.
Application measures which institutional setting buys or deploys diagnostic imaging AI. Procurement differs between publicly funded radiology departments, private hospital groups, independent imaging centers and remotely staffed interpretation services.
Public Hospital represented an estimated ~34% of 2025 revenue. NHS England is expanding chest X-ray AI to trusts after reporting more than four million patients received faster lung-cancer assessment or an all-clear; public buyers emphasize reproducible safety and procurement value.
Private Hospital groups use automated CT triage, MRI reconstruction and radiology dashboards to improve scanner utilization. Enterprise deployment requires consistent algorithms across sites and contracts that cover upgrades, clinical training and security monitoring.
Diagnostic Imaging Centers assess software against reporting turnaround, scan volume and cost per examination. Reconstruction products can increase daily MRI throughput without acquiring another magnet, but measurable workflow gains are necessary to justify recurring fees.
Teleradiology Providers integrate triage alerts and automated measurements into geographically distributed worklists. AI tools support radiologists rather than replace clinical interpretation; inconsistent acquisition protocols and local authorization rules constrain cross-border deployment.
Institutional demand remains tied to documented clinical benefit and integration with existing image archives; standalone algorithm accuracy is insufficient without usable reporting workflows. Public and private hospitals must assess the time needed for radiologist training and data governance before expanding algorithm use. UK government investment in chest X-ray AI and the EDITH breast-screening trial provides a specific procurement pathway, but screening algorithms need prospective evaluation and clear escalation rules before routine adoption.
End users include radiologists, healthcare institutions and imaging equipment OEMs. The buyer and the clinician using an algorithm are often different, especially for enterprise subscriptions and bundled reconstruction products.
Radiologists use automated prioritization, segmentation and reconstruction outputs when reading CT, MRI and mammography studies. The FDA list identifies the authorized intended use of each device, limiting claims beyond its cleared indications.
Healthcare Institutions coordinate software validation, procurement, cybersecurity and clinical governance across departments. The NHS EDITH breast-screening trial illustrates how multi-site evaluation may support wider institutional procurement after clinical evidence is reviewed.
Imaging Equipment OEMs embed algorithms into scanner consoles and workstation software. Philips and GE HealthCare have announced AI-enabled reconstruction and image-management products, with value captured through upgrades, subscriptions or attributable intelligent modules.
Hospitals and health systems control most budgets, while radiologists determine practical usability and OEMs influence distribution through installed equipment and technical support. Radiologists remain responsible for clinical interpretation when AI highlights a suspected abnormality or provides quantitative measurements. Hospitals must monitor whether an algorithm performs consistently across different scanner models and patient populations. OEM partnerships can simplify technical deployment but create dependence on software updates and hardware compatibility. GE HealthCare and Philips distribute algorithms through imaging systems, while independent vendors require hospital-level validation before deploying stand-alone software.
Modality adoption reflects the number of examinations, clinical urgency and the availability of authorized algorithms. CT, MRI, X-ray, ultrasound, mammography and nuclear medicine each require distinct validation datasets and workflow interfaces.
UK government funding supports national chest X-ray AI rollout for suspected lung cancer; high study volumes create opportunities for worklist prioritization.
Viz Subdural Plus quantifies subdural collections on non-contrast CT; emergency stroke and pulmonary embolism tools also support time-sensitive review.
Philips SmartSpeed Precise received FDA clearance in July 2025, bringing AI reconstruction to compatible 1.5T and 3T MRI systems.
GE HealthCare and Philips embed image-quality and measurement tools into ultrasound workflows, where operator variability complicates standardization.
The NHS EDITH program is testing breast-screening AI in nearly 700,000 women, with prospective evidence needed before routine scale-up.
GE HealthCare obtained clearance for MIM LesionID Pro in January 2026 to automate aspects of PET/CT and SPECT/CT tumor-burden assessment.
CT and MRI provide demanding image-analysis workloads, while screening programs can create large examination volumes once regulators and clinical purchasers accept performance evidence. GE HealthCare MIM LesionID Pro and Viz Subdural Plus illustrate applications with defined quantitative outputs, while NHS chest X-ray deployment illustrates high-volume triage. Performance should be evaluated within the authorized intended use, and the imaging modality determines the necessary validation datasets, acquisition protocols and reporting interfaces.
The AI Medical Imaging Market reflects distinct regulatory pathways, public imaging programs and hospital budgets. North America leads revenue, while Europe is expanding NHS deployment and parts of Africa are adopting AI-assisted tuberculosis chest X-ray screening.
North America represented an estimated ~44% of 2025 AI medical imaging revenue. The FDA reported more than 1,600 authorized AI-enabled medical devices by September 2026, with radiology accounting for a substantial part of the published list. U.S. hospitals use those records to verify whether a product is authorized for triage, image reconstruction, measurement or another defined purpose. GE HealthCare announced clearance for True Definition DL in April 2026 and MIM LesionID Pro in January 2026, while Viz.ai reported Subdural Plus clearance in June 2025. These applications address different clinical workflows and cannot be substituted without validation. Large health systems may buy multiple algorithms through enterprise contracts, but integration with PACS, cybersecurity controls and local imaging protocols influences implementation cost. Canadian institutions face separate authorization and procurement requirements, creating additional review steps for cross-border suppliers. The strongest opportunities arise where hospitals can document improvements in reporting turnaround, diagnostic consistency or scanner utilization.
The FDA maintains a public list of AI-enabled medical devices and said in September 2026 that more than 1,600 had been authorized for U.S. marketing. The list includes radiology systems and stand-alone software, but authorization is tied to each product’s intended use. GE HealthCare, Viz.ai and other suppliers must demonstrate applicable regulatory compliance before hospitals can deploy their algorithms. Clinical buyers also assess false-alert rates and integration with local radiology reporting systems.
Source: FDA.
European imaging AI purchasing combines publicly funded radiology programs, private imaging networks and requirements under medical-device rules. The UK government announced GBP 20 million in June 2026 to extend AI-supported chest X-ray assessment to every NHS trust in England by 2029. It reported that the technology had already supported faster lung-cancer assessment or an all-clear for more than four million patients. The EDITH breast-screening trial, launched in February 2025, is evaluating AI across 30 sites and nearly 700,000 women. These programs create potential procurement demand but require evidence of safety and reliable workflow integration. The European Commission identifies high-risk obligations for medical AI under the AI Act, including data quality, risk controls and human oversight. Imaging software vendors must also consider national procurement processes, data protection and interoperability with hospital archives. European hospitals may favor platform-level integration where several authorized algorithms can be managed through one radiology workflow, while specialized products still need clinical evidence for their intended use.
The Department of Health and Social Care announced in June 2026 that GBP 20 million would fund broader deployment of AI chest X-ray technology across NHS trusts by 2029. Officials reported that more than four million patients had already benefited from faster lung-cancer assessment or an all-clear. The NHS is also testing breast-screening AI through EDITH. Public purchasers need evidence of clinical benefit, safe escalation and integration with existing radiology teams before expanding contracts.
Asia-Pacific markets include advanced scanner fleets in Japan and Australia alongside large hospital expansion programs in India and China. Philips described a June 2025 implementation at Kasturba Medical College Manipal in India, where CT Smart Workflow improved patient positioning, image reconstruction and examination processes. The case illustrates demand for AI functions embedded in equipment rather than only independent image-reading software. Regional buyers assess whether algorithms can run on existing CT and MRI installations and whether support teams can train radiographers and radiologists. Country-specific regulatory review, language localization and integration with hospital information systems affect adoption. Smaller imaging providers may prefer usage-based software contracts because they lack the capital budget for new scanner platforms. In high-volume tertiary hospitals, reconstruction and worklist prioritization can improve utilization, but clinical accuracy and alert burden still require monitoring. Demand is therefore linked to measurable workflow improvements, imaging volumes and available clinical staff rather than generalized enthusiasm for AI technology.
Philips published a June 2025 case study describing the deployment of CT Smart Workflow at Kasturba Medical College Manipal. The institution used AI-enabled tools for positioning and image reconstruction to manage a growing number of CT examinations. Philips reported that the implementation helped the department scan more patients daily, while clinicians continued to supervise image interpretation. The example shows how Indian hospital procurement can target scanner throughput and workflow integration rather than stand-alone diagnostic algorithms alone.
Source: Philips.
Latin American AI imaging demand is developing through public radiology modernization, private diagnostic networks and university-led research. In March 2026, Brazil’s federal government highlighted PrioScan, an AI system developed by Hospital de Cl - nicas de Porto Alegre and NeuralMind to help prioritize chest X-rays. The project illustrates a targeted clinical workflow where software may reorder urgent examinations rather than issue an autonomous diagnosis. Brazilian state health authorities also reported deployment of AI-enabled CT equipment at the Hospital de Emerg - ncia do Agreste in March 2026, accompanied by radiology staff training. Public procurement often focuses on scan capacity, local service contracts and affordability, while larger private imaging networks may buy enterprise platforms. Regional vendors must account for data protection, Portuguese or Spanish user interfaces and variable infrastructure between urban centers and rural facilities. Hospitals can justify AI imaging procurement when algorithms are validated on local patient images and radiology departments document shorter reporting delays without compromising clinical oversight.
Brazil’s Ministry of Management and Innovation published information about PrioScan on 11 March 2026, describing an AI tool developed by Hospital de Cl - nicas de Porto Alegre and NeuralMind to prioritize chest X-ray reporting. The tool addresses worklist ordering rather than replacing the radiologist. Such locally developed products can support procurement when public hospitals demonstrate safe performance, reliable integration and a clear escalation pathway for suspected urgent findings.
Source: Brazilian federal government.
Middle East and African imaging AI deployment is driven by different clinical priorities and infrastructure constraints. Gulf health systems may purchase enterprise imaging software and reconstruction tools alongside scanner upgrades, while public health programs in parts of Africa focus on tuberculosis screening and access to radiology expertise. WHO announced in June 2025 that six computer-aided detection software products met its performance standards for tuberculosis screening in people aged 15 and older. These products can help prioritize confirmatory testing but are not substitutes for microbiological diagnosis. Ethiopia launched a national AI-powered digital X-ray screening program in September 2025, supported by WHO guidance and training. Procurement in lower-resource settings depends on portable equipment, stable electricity, maintenance and clinical follow-up capacity. Suppliers need locally validated thresholds and pathways for confirmatory testing, while regional governments assess cost per screened patient rather than the number of AI algorithms offered. Programs with reliable training and quality assurance can support recurring software and equipment demand.
WHO’s Africa office reported in October 2025 that Ethiopia had distributed 225 AI-powered digital X-ray machines for tuberculosis screening after a September national launch. WHO supported training for 75 healthcare workers and the development of national implementation guidance. The rollout demonstrates an identifiable imaging AI use case in public health, but patients with positive computer-aided screening findings still require appropriate confirmatory testing before tuberculosis treatment.
Source: WHO Africa.
AI Medical Imaging Market suppliers compete on the scientific or clinical credibility of their workflows, deployment capacity and the reliability of supporting data. GE HealthCare, Siemens Healthineers and Philips represent different commercial models within the sector. Purchasers compare technical scope, implementation burden and the ability to maintain support over repeated projects or clinical deployments.
GE HealthCare integrates AI functionality into breast ultrasound, CT reconstruction and cardiovascular imaging products. Siemens Healthineers maintains AI-Rad Companion imaging software and associated technical documentation. Both companies can distribute intelligent tools through installed scanner and hospital relationships. The AI-attributable component must be separated from the value of the underlying imaging equipment when assessing software-market revenue.
Philips launched Image Management 15 in November 2025, linking web-based diagnostic viewing with connected AI and reporting tools. Aidoc focuses on clinical AI applications that help prioritize findings within imaging workflows. Hospitals may choose between platform-integrated functions and independent triage software according to PACS compatibility. Clinical validation, cybersecurity and support coverage are important requirements for enterprise contracts.
Viz.ai received FDA clearance for Subdural Plus in June 2025, adding quantitative CT analysis for subdural collections. Qure.ai develops imaging AI tools for radiology and screening workflows, including chest imaging. These companies compete through focused clinical use cases rather than complete scanner portfolios. Hospitals assess intended-use authorization, notification thresholds and the effect on specialist response times.
Annalise.ai and Lunit supply AI-enabled image interpretation technologies aimed at supporting radiology or cancer-related imaging workflows. Specialist vendors can expand through health-system software integration and distribution partners. Each algorithm still requires clinical evidence for its specific indication and appropriate regulatory status in the target market. Pricing may involve enterprise licenses, platform access or usage-linked arrangements.
The FDA authorizes AI-enabled medical devices for defined intended uses and publishes individual device records. Hospitals therefore compare evidence for the exact triage, reconstruction or measurement function being purchased rather than treating all algorithms as equivalent. AI performance can vary across scanner manufacturers, patient populations and imaging protocols, so radiology departments need local validation, clinician oversight and processes for software changes. Contracts must also identify responsibility for cybersecurity, support and audit trails.
Imaging suppliers earn revenue through enterprise software licensing, per-examination fees, integration contracts and identifiable AI functionality embedded in scanners. Conventional CT, MRI and ultrasound equipment sales are excluded unless a separable AI component can be identified. Philips SmartSpeed Precise, GE HealthCare True Definition DL and Viz Subdural Plus illustrate distinct commercial routes for intelligent reconstruction and quantitative imaging. Procurement depends on measurable clinical workflow improvements, not unsupported claims that algorithms replace trained radiologists.
April 2026: GE HealthCare announced FDA 510(k) clearance for True Definition DL, an AI-based CT reconstruction application designed to improve spatial resolution and suppress artifacts. The clearance expands its portfolio of image-quality algorithms and supports upgrades in clinical CT departments. Clinical CT departments can evaluate whether improved reconstruction performance changes repeat-scan rates or examination turnaround. Source
January 2026: GE HealthCare received FDA clearance for MIM LesionID Pro, software that automates aspects of whole-body tumor-burden analysis using PSMA PET/CT and SPECT/CT. Quantification products create opportunities in nuclear medicine and therapy-response workflows. Nuclear medicine programs require reliable segmentation and physician review before acting on automated burden estimates. Source
July 2025: Philips announced U.S. FDA 510(k) clearance for SmartSpeed Precise, a dual-AI MRI reconstruction technology for compatible 1.5T and 3T systems. Vendor-reported performance improvements support interest in upgrading installed MRI scanners without replacing the entire platform. Imaging departments must confirm software compatibility and train staff before realizing the vendor-reported productivity improvements. Source
June 2025: Viz.ai reported FDA clearance for Viz Subdural Plus, which measures subdural hemorrhage features from non-contrast CT images. The product illustrates the move toward specific quantification tools rather than broad claims of autonomous image diagnosis. Emergency departments can integrate the measurements into established reporting and escalation workflows under the cleared indication. Source
February 2025: The UK government launched the EDITH breast-screening AI trial across 30 sites, involving nearly 700,000 women and GBP 11 million in support. Prospective screening trials can influence future purchasing decisions by testing whether AI maintains diagnostic safety. The trial will help determine whether screening accuracy and reader workload justify broader public procurement. Source
Global AI Medical Imaging Market revenue is projected to increase from USD 2.18 billion in 2026 to USD 20.53 billion by 2034, equivalent to a 32.4% CAGR. Software deployment, imaging-system upgrades and workflow integration contribute to forecast growth.
| Forecast variable | 2026 starting condition | 2026–2034 market implication |
|---|---|---|
| Technical adoption | Validated specialist workflows | Wider implementation can support repeat product and service revenue |
| Buyer budgets | Institutional and corporate spending cycles | Capital constraints can delay deployments and outsourced contracts |
| Regulatory quality | Product-specific evidence and compliance | Qualified suppliers may gain access to higher-value projects |
| Regional reach | North America leads in 2025 | Other regions expand as infrastructure and training improve |
The FDA reported more than 1,600 authorized AI-enabled medical devices by September 2026, including many radiology applications. Additional authorizations can broaden available products, but hospital adoption depends on clinical validation and integration with existing reporting systems. Enterprise buyers assess whether an algorithm changes turnaround time or diagnostic workflow under routine conditions. Regulatory clearance for one use does not automatically permit a vendor to market unrelated functions.
The UK government allocated GBP 20 million in 2026 to expand AI-assisted chest X-ray analysis across NHS trusts by 2029. National procurement can create demand for software licenses, integration support and continuous performance monitoring. Hospitals with different PACS environments still need implementation testing and staff training. Evidence of reduced reporting delays will influence renewals more than the number of algorithms included in a platform.
Philips introduced SmartSpeed Precise MRI technology and GE HealthCare launched AI-assisted breast ultrasound and reconstruction tools during 2025. Embedded software can improve scanner productivity, while independent applications can deliver triage or disease-specific measurements. The forecast counts only AI-attributable value from integrated systems rather than entire imaging equipment sales. Buyers will compare workflow gains against capital upgrades, subscriptions and per-scan service fees.
The European Commission published guidance in June 2025 on the interaction between medical-device regulations and the AI Act. Developers serving international hospitals must document intended use, risk management, data quality and post-market performance. These requirements favor vendors able to maintain software versions and clinical evidence across jurisdictions. Expansion in Asia-Pacific and emerging markets also depends on local validation, cybersecurity and radiology staffing.
The AI Medical Imaging Market study addresses market revenue, supplier capabilities, customer purchasing patterns and 2026–2034 demand across five global regions.
The global AI Medical Imaging Market reached USD 1.64 billion in 2025, with a 2026 estimate of USD 2.18 billion. Revenue covers identifiable AI software, imaging-specific integration and incremental intelligent scanner functions. Conventional imaging hardware without separable AI value is excluded from the total.
The forecast CAGR is 32.4% for 2026–2034, taking global AI imaging revenue to USD 20.53 billion by 2034. Growth depends on regulatory authorizations, hospital procurement and measurable gains in image reconstruction, triage and reporting workflows. Hospitals also purchase licensed algorithms and AI functionality compatible with their installed scanner systems.
Software represented an estimated ~79% of 2025 AI medical imaging revenue. The category includes authorized triage algorithms, quantitative imaging applications, reconstruction software and enterprise radiology platforms. Hardware is counted only for identifiable AI functionality, not the full selling price of conventional scanners.
Public Hospital is the largest application category, accounting for an estimated ~34% of 2025 revenue. Public health systems procure AI tools for screening, triage and radiology productivity. NHS England’s chest X-ray rollout and EDITH breast-screening trial provide examples of structured institutional evaluation.
North America is the largest region, representing an estimated ~44% of 2025 revenue. U.S. FDA authorizations, imaging equipment suppliers and large hospital systems support adoption. Europe is expanding publicly funded programs, while Asia-Pacific hospitals are evaluating workflow and scanner reconstruction technologies.
Individual AI-enabled medical devices may receive FDA 510(k) clearance, De Novo authorization or another applicable pathway. The FDA maintains a public list of authorized products and their intended uses. A clearance for CT quantification does not authorize unrelated diagnoses or autonomous treatment decisions.
AI tools can help prioritize examinations, reconstruct images and quantify findings, but radiologists remain responsible for clinical interpretation in many authorized workflows. Hospitals must review false alerts, dataset differences and clinical escalation protocols. The approved intended use of each product determines what claims and deployment practices are permitted.
GE HealthCare, Siemens Healthineers, Philips, Aidoc, Viz.ai, Lunit, Qure.ai and Annalise.ai supply different imaging AI products. Some embed functions in scanners, while others provide independent triage or image-analysis software. Buyers should compare clinical evidence, authorization, compatibility and support rather than treating vendors as interchangeable.
AI reconstruction can improve image quality or reduce acquisition time, while CT algorithms can help identify and quantify defined abnormalities. Philips SmartSpeed Precise received FDA clearance in July 2025, and GE HealthCare announced True Definition DL clearance in April 2026. Clinical deployment requires compatible MRI or CT equipment and validated imaging protocols under the authorized product indication.
Regulatory evidence, cybersecurity, image archive integration, local validation and radiologist training can delay deployment. Algorithms may perform differently across scanners or patient groups, requiring monitoring after installation. Public hospitals also need procurement funding and clinical proof that software improves workflows without increasing unnecessary alerts.
Global revenue is projected to reach USD 20.53 billion in 2034 under the 2026–2034 forecast. NHS chest X-ray programs, FDA-cleared reconstruction products and targeted screening tools support demand. Hospitals will continue assessing whether algorithms improve turnaround, diagnostic quality or scanner capacity within their authorized indications.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.